Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
Eduardo Díaz‐Rubio(Hospital Clínico San Carlos), M. Homerin(Centre Hospitalier René-Dubos), G. Dallavalle(Ospedale San Carlo), C. Boni(Ospedale Santa Maria), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Manuel Benavides(Hospital Clínico Universitario Virgen de la Victoria), Javier Sastre(Hospital Clínico San Carlos), Roberto Labianca(Ospedale Papa Giovanni XXIII), H. Cortés-Funes(Centre Hospitalier René-Dubos), Filippo de Braud(University of Milan)
Cited by 228
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k